Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer.
Saved in:
| Title: | Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. |
|---|---|
| Authors: | Loor A; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mack KN; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA., Bauer D; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ingham A; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pratt EC; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. edwin.pratt@stonybrookmedicine.edu.; Stony Brook University Cancer Center, Stony Brook, NY, USA. edwin.pratt@stonybrookmedicine.edu., Lewis JS; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org.; Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA. lewisj2@mskcc.org.; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org. |
| Source: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2026 Jun; Vol. 53 (7), pp. 4587-4596. Date of Electronic Publication: 2026 Feb 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41760827 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Loor+A%22">Loor A</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Mack+KN%22">Mack KN</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bauer+D%22">Bauer D</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Ingham+A%22">Ingham A</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Pratt+EC%22">Pratt EC</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. edwin.pratt@stonybrookmedicine.edu.; Stony Brook University Cancer Center, Stony Brook, NY, USA. edwin.pratt@stonybrookmedicine.edu.<br /><searchLink fieldCode="AU" term="%22Lewis+JS%22">Lewis JS</searchLink>; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org.; Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA. lewisj2@mskcc.org.; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101140988%22">European journal of nuclear medicine and molecular imaging</searchLink> [Eur J Nucl Med Mol Imaging] 2026 Jun; Vol. 53 (7), pp. 4587-4596. <i>Date of Electronic Publication: </i>2026 Feb 28. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+Berlin%22">Springer-Verlag Berlin </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101140988 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1619-7089 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216197070%22">16197070 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Nucl Med Mol Imaging <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41760827 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00259-026-07820-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4587 Titles: – TitleFull: Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Loor A – PersonEntity: Name: NameFull: Mack KN – PersonEntity: Name: NameFull: Bauer D – PersonEntity: Name: NameFull: Ingham A – PersonEntity: Name: NameFull: Pratt EC – PersonEntity: Name: NameFull: Lewis JS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1619-7089 Numbering: – Type: volume Value: 53 – Type: issue Value: 7 Titles: – TitleFull: European journal of nuclear medicine and molecular imaging Type: main |
| ResultId | 1 |
